BEIJING, Nov. 7, 2018 /PRNewswire/ — HuiyiHuiying (HY), a leading medical imaging artificial intelligence (AI) company in China, today announced the previous close of a strategic investment led by Intel Capital with participation of Beijing Singularity Power Investment Fund (SPC), marking the first investments by the firms in the medical AI sector in China. HY will use the funding proceeds to support its business development, product innovation and talent recruitment initiatives.

HY is a medical imaging AI company committed to implementing innovative computer vision and deep learning technologies in the medical sector. The company has achieved rapid growth since its establishment in 2015 and has received investments from CDH, Delta Capital, Bluerun Ventures and Yield Capital. HY is collaborating with more than 800 medical institutions in China in clinical applications and scientific research projects, including the Chinese PLA General Hospital, Peking Union Medical College Hospital, Beijing Friendship Hospital and several medical associations. The company is expanding its business into overseas markets including the United States, Japan, Southeast Asia, India and Europe.

“After three years of dedicated development efforts, HY is leading medical AI business model implementation by building up data links and service platforms on the digitalization, mobility and intelligence of medical imaging,” said Dr. Xiangfei Chai, Founder and CEO of HY. “HY launched a series of innovative solutions based on our new patient-oriented product design principle, including the AI research platform for aortic dissection, which is the world’s first automatic segmentation of type B aortic dissection. Committed to cross-disciplinary talent development, HY sets up joint laboratories with leading medical and research institutions in China to cultivate professionals with both engineering and medical know-how.”

HY and Intel previously established a joint AI laboratory and this new investment from Intel Capital further extends their collaboration. In September 2018, Intel and HY announced the two companies will work together to develop an AI full-cycle breast health management cloud platform to support breast cancer screening and diagnosis. HY will use the investment from Intel Capital to help enhance its R&D capabilities, broaden its market reach and further grow its business as a leading medical AI solution provider.

Anthony Lin, Vice President and Managing Director of Intel Capital International, said: “Intel is committed to promoting data-driven technological innovation and supporting the exploration of AI breakthroughs and application implementation in China’s high-technology industry. HY is a leading company in the development and implementation of AI in the medical sector. We believe data combined with smart technology applications can help address major challenges within the medical industry and we look forward to working with HY to find AI-led solutions that contribute to improved health outcomes.”

SPC was established in 2015 by the National IC Industry Investment Fund, BOE Technology Group and Yizhuang SDIC. Jiaheng Wang, Managing Director of SPC, said: “We focus on investing in leading AI companies with promising prospects and maturing business models. HY has a comprehensive team with deep knowledge and insights of the medical industry. Clear development strategies, leading R&D ability, strong market expansion capability, and fully recognized customer core values all contribute to HY’s success of implementing AI in the medical industry. SPC will collaborate with HY to advance the development of AI for China’s medical industry.”

About HuiyiHuiying (HY)

Established in 2015, HuiyiHuiying is a medical imaging artificial intelligence company focused on computer vision and deep learning. Headquartered in Beijing, HY has offices in Silicon Valley, Hong Kong, Suzhou and Guangzhou. With strong R&D and business implementation capabilities, HY is an industry leader offering product lines from scientific research to clinical practice. HY implements AI in the full medical process for single disease, from screening, diagnosis to a complete prognosis prediction. HY’s multi-modal, full imaging data link is leading the industry in China. For more information regarding HY, please visit www.huiyihuiying.com.

About Intel Capital

Intel Capital invests in innovative startups targeting artificial intelligence, autonomous driving, workload accelerators, 5G connectivity, virtual reality and a wide range of other disruptive technologies. Since 1991, Intel Capital has invested US $12.3 billion in over 1,530 companies worldwide, and more than 660 portfolio companies have gone public or been acquired. For more information on what makes Intel Capital one of the world’s most powerful venture capital firms, visit www.intelcapital.com.

About Beijing Singularity Power Investment Fund L.P. (SPC) 

Beijing Singularity Power Investment Fund L.P. (SPC) was established in 2015 by the BOE Technology Group, National IC Industry Investment Fund, Yizhuang SDIC, and industry leaders. SPC is headquartered in Yizhuang, Beijing, and has research centers in different IC innovation areas including Zhongguancun in Beijing and Silicon Valley in the USA. The initial investable funds of SPC totaled RMB 4 billion (USD 600m). SPC’s investments mainly focus on integrated-circuit design, human-computer interaction, the Internet of Things and Artificial Intelligence.

View original content:http://www.prnewswire.com/news-releases/huiyihuiying-closes-funding-round-led-by-intel-capital-300745347.html

SANTA CLARA, California, Nov. 7, 2018 /PRNewswire/ — A team of researchers from the Dr. Rath Research Institute in California has developed a cancer vaccine effective in reducing tumor growth. This peptide-based vaccine targets specific enzymes called metalloproteinases (MMPs) that are necessary for any cancer to grow tumors, metastasize, and form blood vessels in tumors (angiogenesis). The Dr. Rath research team showed that test mice, vaccinated with peptides containing specific sequences from MMP-2 and MMP-9 and subsequently challenged with melanoma cancer cells, had an average reduction in tumor volume by about 76% compared to unvaccinated controls. Notably, some vaccinated animals did not develop any cancer at all.

California research team publishes promising results from peptide based universal cancer vaccine

The study was published in October 2018 in the online Journal of Cellular Medicine and Natural Health.

With cancer remaining the second largest epidemic killing more than 7 million people each year this new therapeutic approach has a potential to change it. Compared to monoclonal antibodies (Mabs) or biosimilar molecules recently developed to combat cancer, the anti MMP vaccine approach promises to be much more effective as well as affordable in the global fight against the disease. While Mabs/biosimilars are directed against one specific type of cancer, the anti-MMP vaccine can target all types of the disease at once. Moreover, while the Mabs/biosimilars generally require an injection once or twice each month, the anti-MMP vaccine would require one single vaccination with potential boosts only after several years.

The anti-MMP vaccination – if developed successfully – could be offered to the public by national or international health services at a reasonable cost.

To protect this valuable technology from being made unaffordable to the majority of patients and nations, the Dr. Rath Research Institute has obtained patent protection for it in many countries. The Institute is looking for public research institutes, government research organizations, and other non-profit institutions to co-develop this promising technology with the goal to successfully treat, prevent, and eventually eliminate cancer.

Source:   https://www.jcmnh.org/peptide-vaccines-directed-against-human-metalloproteinases-mmps-with-anti-tumor-efficacy-in-vitro-and-in-vivo/

US Patents No. 8003110 and 8067009

Photo – https://mma.prnewswire.com/media/780637/Dr_Rath_Cancer_Vaccine.jpg

Source: Dr. Rath Research Institute

SHANGHAI, Nov. 7, 2018 /PRNewswire/ — On November 6, China’s leading one-stop healthcare ecosystem platform Ping An Good Doctor (01833.HK) announced that the first commercially operational unmanned clinic in China, which it researched and developed, “One-minute Clinics” has been formally revealed in a scenic area in Wuzhen. It will provide a high-speed, convenient, one-stop shop for medical and healthcare services for nearby residents, visitors to the scenic area and guests of the 2018 World Internet Conference.

The First “Unmanned Clinic” Reveals Itself in Wuzhen; Ping An Good Doctor Uses AI Technology to Empower a Healthy City

The “One-minute Clinics” includes two major functional modules, an “Independent Advisory Room” and an “Smart Medicine Cabinet.” The patient need only sit in the “Independent Advisory Room” to be able to speak with a cloud computing doctor. By providing a description of the ailment as well as medical examination, it is possible to obtain a preliminary diagnostic suggestion for the illness. After the medical consultation is over, the patient may, based on the doctor’s recommendation, immediately pay and obtain medicine from the nearly “Smart Medicine Cabinet.” Presently, “One-minute Clinics” cover more than 100 commonly seen drugs. In regards to drugs that cannot be placed, the user may also purchase online using the Ping An Good Doctor smartphone application and then receive the drug from nearly pharmacies with a “one hour drug delivery” service.

The relevant person-in-charge in Ping An Good Doctor explained that, due to the utilization of the most up-to-date intelligent technologies such as artificial intelligence, big data, internet remote consultation, etc., and by combining multiple types of intelligent medical examination equipment, “One-minute Clinics” can provide to the user self-serve medical and healthcare services such as medical advice, rehabilitation guidance, drug taking advice, to-be-paid-for drugs, etc., which greatly saves the visit time of the user. During the one week when it was put into trial operation in Wuzhen’s scenic area, the daily average advisory volume has approach 100 persons.

In the future, Ping An Good Doctor’s “One-minute Clinics” will be popularized in public areas such as pharmacies, communities, enterprises, schools, scenic areas, markets, highway service stations, etc. Combined with Ping An Good Doctor’s offline network of 3100 new hospitals and more than 60,000 neighborhood clinics, this creates a one kilometer medical service circle, and quickly satisfies the real time medical and healthcare needs of city residents. It contributes to the construction of a healthy city. It is expected that by the end of 2018, “One-minute Clinics” will expand to 1000 units across China.

“Small frame” hides AI black technology

Without any need to register or wait in line, chronic disease and often seen disease may be diagnosed and treated with drugs within a few minutes. This “One-minute Clinics” conceals “AI black technology” within three square meters. When the patient is seeking advice, firstly, the AI Doctor receives the patient. It can communicate with the patient through language and graphics. It can lead patients to accurately describe symptoms. It can form a structured medical history and provide an intelligent diagnosis plan for back office expert physicians to examine. Once a physician has followed up on the visit, “AI Doctor” can combine the relevant diagnostic structure of physicians make a smart prescription for drugs. The foregoing thereby results in the intelligent transformation of the entire visit and enhances the efficiency of the visit.

The relevant person-in-charge at Ping An Good Doctor expressed that AI Doctor is researched and developed by an AI team formed from over 200 world class artificial intelligence experts and has been trained using data from over 300 million visits and consultations. Currently, AI Doctor can cover over 2000 commonly seen diseases and can achieve instant answer upon questioning for tens of thousands of medical and healthcare questions in order to help the accuracy of medical treatment achieve world’s leading.

After the AI Doctor’s work has been completed, the back office expert physicians will engage in focused supplementary advisory based on the structured medical history of the patient that is created by the AI Doctor and verify the diagnosis and advice of the AI Doctor. At the same time, it gives the patient more humane care. Presently, Ping An Good Doctor has already hired a large volume of highly qualified physicians from the top three hospitals. Its own physician team exceeds 1000 persons. Its external network of partnering physicians reach nearly 5000 persons. Through having ample number of excellent physicians together with the world’s leading AI black technology, the accuracy and security of the “One-minute Clinics” online advisory procedure is guaranteed.

To be popularly used in public service spaces realize commercial insurance direct pay

Overly crowded Grade IIIA hospitals is a clear illustration of contrast with respect to the issue of having difficulty obtaining healthcare in China presently. Ping An Good Doctor’s “One-minute Clinics” is expected to become a powerful tool in resolving the “medical visit dilemma”.

Information coming from a third-party research institute Frost & Sullivan shows that, in 2016, including transport and waiting-in-line times, Chinese patients consume 3 hours per visit on average. The real time for physician’s diagnoses averages only 8 minutes per visit. The terrible medical care experience leads patients to complain with bitterness. Even for a commonly seen disease such as a cold or a headache, it is common to wait for several hours for registration and lining up.

If everybody can resolve the medical care needs associated with commonly seen diseases and chronic disease in the convenient of their office, home and in the community, it will help relieve the congestion. Ping An Good Doctor’s “One-minute Clinics” is a totally new attempt to resolve the issue of the “medical visit dilemma” using AI medical technology. Presently, “One-minute Clinics” has already been put into operation in many public areas such as Industrial Bank, China Unicom, BiliBili, Evergrande Healh Valley, Country Garden, etc. and achieved quite good results.

“Presently, the most pressing need for ‘One-minute Clinics’ are located in public service areas and large enterprises,” says the relevant person-in-charge from Ping An Good Doctor, “the placement of ‘One-minute Clinics’ in high foot traffic areas such as markets and scenic areas can replace a traditional clinic (two physicians and two nurses) and results in the savings of major amounts of medical personnel costs every year. It can also allow the patient’s visit and drug purchases to be more convenient and save time and money. At the same time, with respect to the clients of Ping An old age insurance, the ‘One-minute Clinics’ has already realized the direct payment of commercial insurance. The user may use the healthcare card of Ping An old age insurance to pay for the ‘One-minute Clinics’ service, which is convenient and quick.”

About Ping An Good Doctor (1833.HK)

Ping An Good Doctor is the leading one-stop healthcare ecosystem platform in China. By combining “mobile health + AI technology”, the Company strives to provide every family with a family doctor, every person with an e-health profile and everyone with a healthcare management plan. Ping An Good Doctor has established a comprehensive, one-stop healthcare ecosystem covering family doctor services, consumer healthcare services, a health mall as well as health management and wellness interaction.

As of the end of June 2018, there were 228 million registered users and the Company’s MAU reached 48.6 million. Ping An Good Doctor is today the largest mobile medical application in China in terms of user scale. Ping An Good Doctor employs more than a thousand medical personnel (Assistant Supervisor Level or above from Class III Grade A Hospitals) in its in-house medical team and contracts with 4,650 renowned external doctors. This in-house medical team, empowered by our proprietary AI technology, provides users with 24 x 7 online consultation services. In our offline partnership network, Ping An Good Doctor collaborates with approximately 3,100 hospitals (including more than 1,200 Class III Grade A hospitals) to provide services such as hospital referral, appointment and inpatient arrangements. Ping An Good Doctor also partners with more than 2,000 healthcare institutions, including physical examination centers, dental clinics, cosmetic surgery institutions and more than 10,000 pharmacy outlets, to provide relevant health and wellness services to our users. By integrating our AI-empowered medical team, external doctors and offline network, Ping An Good Doctor has established a closed-loop healthcare ecosystem which enables our users to enjoy online consultations and online drug purchases, as well as online consultations and offline follow-up treatment, thereby providing convenient, high-quality and efficient family doctor services.

In April 2015, the App “Ping An Good Doctor” was officially launched. In May 2016, the Company completed an A round financing and raised US$500 million. In December 2017, the Company completed the pre-IPO financing from Softbank Vision Fund, during which it raised US$400 million. On 4 May 2018, Ping An Good Doctor became the No.1 listed internet health-tech company in the world when it joined the Hong Kong Stock Exchange, stock code 01833.HK. Our IPO cornerstone investors include Blackrock, Capital Group, GIC, Canada Pension Plan Investment Board, Khazanah Nasional Berhad, Swiss Re and CP Group.

Photo – https://photos.prnasia.com/prnh/20181106/2290868-1

• Mundipharma will provide Emtrix^® for patients suffering from nail fungus and nail psoriasis in the Middle East and Africa.      
• Rights secured in agreement with Swedish company Moberg Pharma, a specialist in topical treatments for nail and skin diseases.
• Emtrix^® to be distributed in the region under Mundipharma’s popular BETADINE^® brand.

DUBAI, United Arab Emirates, Nov. 7, 2018 /PRNewswire/ — Mundipharma has signed an agreement with Moberg Pharma to commercialize Emtrix^® — its leading product for nail fungus and nail psoriasis — in the Middle East and Africa under Mundipharma’s BETADINE^® consumer healthcare brand.

Fungal infections can cause onychomycosis, which can result in thickening, splitting, roughening and discoloration of both toenails and fingernails. It is estimated that about 2% to 13.8% of adults are affected by onychomycosis,[I], [ii], [iii] and the prevalence increases with age reaching 25 – 30% in the elderly.[iv], [v] Infections can be painful, impact a patient’s self-image and are associated with increased risk of secondary infection. Left untreated, it can cause serious limitations to mobility.[vi]

Applied to deformed nails resulting from fungal infection, such as onychomycosis, as well as psoriasis that occurs in nails, Emtrix^® improves the appearance of damaged nails by reducing discoloration, normalizing thickness, and hydrating brittle nails. [vii], [viii], [ix],[x]

Mundipharma CEO, Raman Singh, said: “This agreement is another example of Mundipharma expanding its operations to provide better healthcare options for more patients. Many more people will now be able to access one of the leading products for these common and uncomfortable conditions.

“This addition complements Mundipharma’s existing portfolio of BETADINE^{®^} treatments, including infection control products, which have been trusted by healthcare professionals and consumers around the world for over 50 years.”

“We look forward to developing our relationship with Mundipharma and making Emtrix^® available in new regions as we expand our footprint in growing markets”, says Peter Wolpert, Moberg Pharma’s CEO.

About Mundipharma           

Mundipharma is a network of independent associated companies, which are privately owned entities covering pharmaceutical markets in Asia-Pacific, Latin America, the Middle East and Africa. The headquarters for these territories is in Singapore. Mundipharma consistently delivers high-quality medicines while standing by the values it represents. Its mission is to alleviate the suffering of patients and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.

About Moberg Pharma

Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 30 countries. The company’s portfolio includes the OTC brands Kerasal^®, Kerasal Nail®, New Skin^®, Dermoplast^® and Domeboro^®. Kerasal Nail^® (Emtrix^®, Zanmira^® or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two assets in late-stage clinical development, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB). 

For more information, please visit:  www.mobergpharma.com

Photo – https://photos.prnasia.com/prnh/20181106/2290778-1LOGO  

GUANGZHOU, China, Nov. 6, 2018 /PRNewswire/ — The 124th China Import and Export Fair (Canton Fair), has gathered more than 8,600 companies from the areas of textiles and garments, shoes, cases and bags, recreational products, medicine and healthcare products and food to showcase their market-driven ideas and designs to global buyers during its Phase 3 exhibition.

Fashion Products Highlight Market-driven Design at 124th Canton Fair

“The Canton Fair is linking global demands with local designing and manufacturing capabilities, and now we can see that the design of the products displayed during Phase 3 of the Canton Fair are in accordance with the structural changes in the consumer market, which also match global buyers’ needs,” said Maggie Pu, Deputy Director General of the Foreign Affairs Office at Canton Fair. “We are privileged to witness the progress our exhibitors and buyers have made through their visit to the Canton Fair.”

Coming from the largest country in the global textile and garment industry with the most complete industrial chain and categories, exhibitors from the Textile and Garment section are not only offering one-stop purchase of quality products, but they are also aiming to transform their processes to meet market demand and increased competition.

With consumer behavior continually changing, exhibitors in the clothing exhibition zone are showing an increasing focus on tailored premium products.

Jack Zhu, Merchandise Manager of Zhejiang Jiaxin Silk Corp., Ltd, a high-end silk clothing manufacturer, noted that their signature product, silk clothing, is welcomed by European and American buyers, while they’re also introducing value products that use silk-blended fabrics and silk cotton to accommodate different purchasing needs.

The Case and Bags section offers more highlights in upgraded product design. With more than 70% market share, 20,000 Chinese manufacturers have produced more than one-third of all cases and bags sold around the world, and they are constantly seeking breakthroughs in product design, distribution channels and branding. This year, exhibitors are introducing new materials and technologies at the Canton Fair.

Xiangxing Group, China’s largest case manufacturer, which produces travel bags and sports bags, is bringing their latest carbon fiber/aluminum material suitcases and bags. “Our latest design fully reflects current popular trend styles and types for cases and bags in the market,” said Crystal Zheng, foreign trader in the company’s International Department. “Canton Fair is the best platform to present and expand our product categories to target different markets with different potential designs, such as offering functional backpacks for North American consumers, colorful designs for South American clients and designer styles for Japanese customers.”

For more information, visit: http://www.cantonfair.org.cn/en/index.aspx.

About Canton Fair

The China Import and Export Fair, also known as the Canton Fair, is held biannually in Guangzhou every spring and fall. Established in 1957, the fair is now a comprehensive exhibition with the longest history, highest level, largest scale and largest number of products as well as the broadest distribution of buyer origins and the highest business turnover in China.

Photo – https://photos.prnasia.com/prnh/20181106/2290805-1

PMD Solutions offers the world’s only continuous, motion-tolerant RR monitor

LONDON, Nov. 6, 2018 /PRNewswire/ — Based on its recent analysis of the European non-invasive respiratory monitoring market, Frost & Sullivan recognises PMD Solutions with the 2018 European Visionary Innovation Leadership Award for its forward-looking wearable respiratory rate (RR) monitoring solution, RespiraSense. PMD Solutions’ vision is to address the global technological deficit of robust tools to measure RR, which is an important early indicator of pending adverse events. PMD Solutions’ differentiated and focused go-to-market strategy is proving highly successful as the company gradually ascends to the top of the non-invasive RR monitoring market.

Frost_And_Sullivan_PMD_Solutions_Award

“Through clinical trials and studies, RespiraSense has demonstrated its ability to detect patient deterioration up to 12 hours earlier than with other existing standard-of-care solutions. In addition, RespiraSense is 80% sensitive and specific to alerts when a patient is experiencing respiratory alkalosis or metabolic acidosis,” said Brahadeesh Chandrasekaran, Industry Analyst. “This efficient, technologically sophisticated solution for clinical patient care in acute care settings, across the continuum of care, endows PMD Solutions with a competitive advantage in the vital signs monitoring market.”

One of RespiraSense’s stand-out benefits is its continuous RR monitoring. Standard continuous RR measurement involves manually counting and measuring a patient’s breath, which is a highly error-prone process. The other standard method is capnography, which requires patients to wear tubes in their noses and around their ears. This method restricts movement and speech and is vulnerable to motion-associated inaccuracies as well. In contrast, RespiraSense uses propriety dynamic algorithms that remove extraneous noise to generate more accurate and reliable RR measurements continuously, even in alert or active patients. This feature is attracting significant interest from hospitals across Europe, the Middle East, and India (EMEA), North America, as well as in select countries in Asia-Pacific.

As hospitals worldwide rapidly align with the Mega Trend of Preventive Healthcare, PMD Solutions has optimally marketed RespiraSense because it employs novel sensor technology to calculate the RR and allows providers to prevent patients’ conditions from deteriorating. By incorporating long-range, macro-level Mega Trends in its innovation strategy, PMD Solutions can potentially be first-to-market with continuous non-invasive RR monitoring solutions.

“RespiraSense is a result of PMD Solutions’ dedication to identifying and prioritizing future growth opportunities continuously and leveraging both internal and external resources. Because of this commitment to innovation, the company’s platform is finding a range of new applications, such as population screening for sleep apnea and screening for dysfunctional breathing at primary care settings,” noted Brahadeesh. “Overall, RespiraSense’s growing clinical support and acceptance make PMD Solutions the company to watch in the European non-invasive respiratory monitoring market.”

Each year, Frost & Sullivan bestows this award upon the company that demonstrates excellence in growth and customer value. The award recognises the superiority of the product/service as well as the overall customer, purchase, ownership, and service experience offered that results in the recipient company seeing above-market growth and greater share of wallet. In addition, the award lauds the company’s growth, diversification, and sustainability strategies.

Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About PMD Solutions
PMD Solutions is the leader in non-invasive respiratory rate monitoring solutions. PMD is focused on developing innovative and patient-friendly technologies to support healthcare provider’s early prevention model of patient care. Established in 2011 on a fundamental clinical need to measure patients breathing rates, which is amiss, is a significant indicator of deterioration, the company develops groundbreaking medical devices for the monitoring and diagnosis of respiratory conditions with the fundamental belief of making every breath count. With several clinical applications, the primary focus of the technology addresses the global technological deficit of accurate and continuous respiratory rate monitoring. Core products include class-leading continuous and motion-tolerant respiratory rate monitors and population sleep screening diagnostic devices.

PMD Solutions operates from Cork, Ireland, a region recognised as one of the largest exporters of medical products in Europe and one of the five global emerging medical device hubs.

Contact: info@pmd-solutions.com 
Web: http://www.pmd-solutions.com/ 
Join the conversation on Twitter: @PMD_Respiratory and #MakingEveryBreathCount

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, collaborates with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, Frost & Sullivan has been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

Contact:

Samantha Park
P: 210.247.2426
F: 210.348.1003
E: samantha.park@frost.com

HONG KONG, Nov. 5, 2018 /PRNewswire/ — Ms. Kimberly Nearing, the Managing Director, Head of Life Sciences at Cedrus Investments (“Cedrus”), was invited to speak on a panel at the Life Sciences Summit held on 25^th October at the Time Warner Center in New York City.

The Life Sciences Summit is an investor and business development conference focusing on emerging companies and academic innovators.  The objective of the event is to connect biotech innovators with potential financiers and industry partners they will need to move new discoveries into clinical development.  Participants included: a Partner, Third Rock Ventures; Senior Director Business Development, AstraZeneca; Executive Director, Merck; a MD from the Memorial Sloan-Kettering Cancer Center; Oncology External Innovation, Eli Lilly; a Partner, Venrock; Senior Advisor, Aisling Capital; Managing Director, Evercore; a Partner, Canaan Partners; and Principal, Merck Ventures.  

Ms. Nearing participated in the Cross-border Investment and Partnering Opportunities panel. Ms. Nearing’s fellow panelist included: Dr. Michael Baran, PhD, MBA, Principal, Pfizer Ventures and Executive Director, External Science & Innovation, Oncology Research, Worldwide R&D, Pfizer, Inc., Dr. Xiaodong (Eric) Wu, International Business Development Manager, Qilu Pharmaceutical, and Dr. Yan Zhang, PhD, Investment Director, Cowin Capital. The panel engaged in lively discussion about the following: 1) What Chinese investors and companies are looking for? 2) How do Chinese investors negotiate for value of early-stage life sciences companies? 3) What are the key challenges in conducting cross-border deals/partner search and how to avoid them?

Ms. Diane Fabel, Director of Operations, Center for Biotechnology & Long Island Bioscience Hub, Executive Director, Life Sciences Summit, said, “As Head of Life Sciences at Cedrus Investments, Ms. Nearing brings a wealth of expertise and insight into US/China cross-border investments and strategic partnerships.  Her more than 20 years of experience in the life sciences industry, coupled with extensive transaction based experience in raising capital and fostering strategic alliances at the highest levels, contributed significant value to the plenary discussion and our Life Sciences Summit delegates.”

About Cedrus Investments

Cedrus Investments is a global boutique investment firm headquartered in Hong Kong, specializing in Asset Management and Financial Advisory Services. Cedrus has extensive experience and a global network in the life sciences industry together with cross-border transactions in geographies including China, Australia, Asia, U.S., and Europe.

Media Enquiry:
Cedrus Investments Ltd.
Amy Sin
+852-3519-2828
information@cedrusinvestments.com

Logo – http://photos.prnasia.com/prnh/20150930/8521506461LOGO

Medical clearance and local partnership enable diagnostic use of Materialise Mimics Innovation Suite in Thailand

LEUVEN, Belgium, Nov. 5, 2018 /PRNewswire/ — Materialise NV (NASDAQ: MTLS) has been cleared to bring the Materialise Mimics Innovation Suite software (Mimics Medical, 3-matic Medical) to the Thai market. This clearance is an important milestone for the Thai healthcare system as it will enable medical experts to use 3D planning software to design a patient-specific treatment approach instead of adapting a patient’s defect to possible solutions. In addition Materialise announces that HARN Engineering will become a distributor of the image-processing software in Thailand.

Mimics Innovation Suite

The 3D medical software Mimics Innovation Suite (Mimics Medical, 3-matic Medical) by Materialise provides researchers, engineers, and surgeons with the most advanced toolkit to create image-based accurate 3D printed models, design medical devices that fit each patient’s unique anatomy, and plan procedures preoperatively which help surgeons make better-informed decisions.

Having surgeons that are better prepared before even entering the operating room is a key benefit to patients as well: the Mimics Innovation Suite software is designed to allow surgeons to simulate each procedure virtually and to evaluate crucial parts of the surgery preoperatively. Moreover, the 3D software helps improving patient communication and can be used for educative purposes to train future health experts.

Global increase of patient-specific solutions

The Thai Food and Drug Administration (TFDA) clearance aligns with the global increase of patient-specific treatment approaches and is yet another example of how the medical 3D software created by Materialise meets the highest quality requirements.

Earlier this year, Materialise (Nasdaq: MTLS) was the first company in the world to receive an FDA clearance (United States) for software intended for 3D printing anatomical models for diagnostic use with Materialise Mimics inPrint, a workflow-based package developed to allow clinicians and hospital technicians to easily prepare a 3D model for 3D Printing, or advanced visualization based on medical images.

Local distribution enabled by HARN Engineering

To support the implementation of the Mimics Innovation Suite software within Thai healthcare facilities, Materialise will work with local distributors, including HARN Engineering to serve the market.

“The medical clearance, allows us to enable more health experts to do 3D planning and  design patient-specific solutions made possible by 3D planning. Both surgeons and patients will benefit from this,“ says Sebastian De Boodt, MIS Portfolio Manager

Dr. Jain Charnnarong, Director, Chairman of Innovation and Incubation Committee of HARN Engineering said, “Helping bring the possibilities of 3D medical software to the Thai healthcare industry means a lot to us. From now on, surgeons will be able to plan procedures virtually, which means patients can benefit from reduced surgery times and fewer risks. We are proud to implement our proven expertise to help bring the benefits offered by medical 3D software into focus.”

About Materialise

Materialise incorporates 28 years of 3D printing experience into a range of software solutions and 3D printing services, which together form the backbone of the 3D printing industry. Materialise’s open and flexible solutions enable players in a wide variety of industries, including healthcare, automotive, aerospace, art and design, and consumer goods, to build innovative 3D printing applications that aim to make the world a better and healthier place. Headquartered in Belgium, with branches worldwide, Materialise combines the largest group of software developers in the industry with one of the largest 3D printing facilities in the world. For additional information, please visit: www.materialise.com.

About Materialise Medical

Materialise Medical, which has pioneered many of the leading medical applications of 3D Printing, enables researchers, engineers and clinicians to revolutionize innovative patient-specific care. Materialise Medical’s open and flexible platform of software and services, Materialise Mimics, forms the foundation of Medical 3D Printing in clinical as well as research environments, offering virtual planning software tools, 3D-printed anatomical models, and patient-specific surgical guides and implants. For additional information, please visit: materialise.com/medical.

About HARN Engineering

HARN Engineering Solutions Public Company was established in 1965 as an engineering trading firm. HARN has gradually expanded into Refrigeration, Safety and Fire Prevention, as well as Digital Printing. We have slowly become one of the leaders in each segment with design, installation, service, and consultation turning ourselves into a solution provider. In 2014, one of our companies was listed under MAI market and, through M&A, the entire group became public in 2016. In our early days, HARN was one of the first distributors for medical devices in Thailand. We, however, focus to return to biomedical with 3D printing using our long experience in digital printing. 

Visit: www.materialise.com
Twitter: @MaterialiseNV

Photo – https://photos.prnasia.com/prnh/20181031/2285099-1

SUZHOU, China, Nov. 1, 2018 /PRNewswire/ — Adagene, Inc., an innovative antibody engineering and discovery company, today announced the dosing of its first patient in its Phase I trial in American for its lead product ADG-106, a fully human agonistic monoclonal antibody (mAb) targeting a novel epitope of CD137. Adagene is also announcing a record speed of review and acceptance of their IND in China for ADG-106. Adagene will investigate the safety and efficacy of ADG-106 therapy as a single agent across a range of solid tumor and non-Hodgkin lymphoma patients in the Phase I clinical study.

“I have worked on this target previously and believe 4-1BB agonists have tremendous therapeutic potential in immunotherapy by targeting the costimulatory pathway,” said Anthony W. Tolcher, M.D., FRCPC, Founder, CEO and Director of Clinical Research at NEXT Oncology (San Antonio, Texas) and an investigator on the trial. “Our team is eager to evaluate ADG-106 because it has shown both excellent safety and efficacy in numerous native preclinical models, and we look forward to assessing the clinical benefit of ADG-106 via its novel mechanism of action that would potentially expand the opportunity for patients to benefit from a novel IO target in both single and combinational therapy.”  

“The initiation of a Phase I clinical study of ADG-106 is a pivotal milestone for Adagene and our novel approach to improving cancer care,” said Peter Luo, CEO of Adagene. “Also, we are honored to receive the IND approval from the NMPA (National Medical Products Administration) in an expedited time. We believe it shows their commitment to support drugs with novel biology and mechanism of action. The preclinical evidence shows we are targeting a novel epitope and the antibody behaves very differently compared with the other two monoclonal antibodies previously in the clinic.”

Additional information will be available shortly on the clinical trial at www.clinicaltrials.gov.

About CD-137 (4-1BB)

CD137 or 4-1BB, a member of the tumor necrosis factor (TNF) receptor superfamily is a promising immune-oncology target. Ligation of CD137 induces a co-stimulatory signal on activated CD8+ T cells and natural killer (NK) cells, resulting in proliferation, increased pro-inflammatory cytokine secretion, and cytolytic function. 4‐1BB co-stimulation is the clinically validated pathway for the optimal T cell activation and its anti-tumor response as highlighted by the successful approval of the 4‐1BB-containing CART therapy by the US FDA.

About Adagene

Adagene (Suzhou, China and San Francisco, California) is an innovative antibody engineering and discovery company, by utilizing its proprietary Dynamic Precision Library Platform (DPL), Adagene is showcasing its exceptional antibody engineering capabilities by building franchises of products that are second and third-generation antibodies.

The company’s management team is composed of industry veterans with a proven track record in therapeutic antibody R&D. Adagene is backed by top notch global venture funds such as F-Prime Capital Partners, Eight Roads Ventures, Wuxi Pharmatech Healthcare Fund I L.P., GP Healthcare Capital, New World TMT Ltd and Sequoia China. The company has raised over $85 million through its series A to C financing.

View original content:http://www.prnewswire.com/news-releases/adagene-announces-first-patient-dosed-in-united-states-and-acceptance-of-ind-in-china-for-adg-106-300741096.html

GREENVILLE, N.C., Nov. 1, 2018 /PRNewswire/ — Metrics Contract Services (Metrics), a division of Mayne Pharma Group Limited, has added a Gerteis Mini-Pactor® roller compactor to its granulation capabilities at its new US$80 million oral solid dose commercial manufacturing facility in Greenville, North Carolina, USA. Metrics became a leader in dry granulation development and clinical manufacturing services after it purchased its initial Gerteis Mini-Pactor in 2014.

The Gerteis Mini-Pactor allows optimization within a range of press forces, roller speeds, and gap settings using knurled, smooth, toothed or custom rollers with a production output of up to 100kg/hr. These roller compactors will now be used for early phase formulation development, clinical trial production through to commercial manufacture.

In addition to the investment in dry granulation capabilities, the company’s recently opened manufacturing facility in Greenville includes newly purchased equipment from manufacturers such as Glatt, Thomas, O’Hara and IMA. Metrics is now able to offer clinical and commercial scale, solvent capable, fluid-bed processing and film coating, wet granulation, tableting, encapsulation, and pan-coating. The new facility more than quadruples the company’s capacity to manufacture oral solid dose pharmaceuticals products to well over 1 billion doses and increases significantly our capacity to manufacture potent compounds.

Metrics’ Executive Vice President Kimberly McClintock said, “With completion of our new commercial manufacturing facility and the success of our client’s clinical programs, it was time to add a second Gerteis roller compactor for use in commercial production. Based on the anticipated lot size and annual demand of the products progressing toward commercialization, the Mini-Pactor was the right choice for throughput and ease of tech transfer to commercial production. This supports our strategy to be a leading small molecule oral dosage form producer for targeted specialty medicines being developed today.”

To date, Metrics has supported over 20 clinical programs using the original Gerteis Mini-Pactor in the drug product manufacturing process. The first programs developed with the clinical Mini-Pactor are now progressing towards submission and commercialization. 

About Metrics Contract Services

Metrics Contract Services is a full-service pharmaceutical development and manufacturing organization serving clients worldwide delivering proven scientific and operational excellence for oral dosage forms.

Metrics’ areas of expertise include quality pharmaceutical formulation development; first-time-in-man formulations; Phase I-III clinical trial materials manufacturing; and analytical method development and validation services leading to commercial scale manufacturing.

Technical capabilities include highly potent, cytotoxic and unstable compounds; Schedule II-V controlled substances; and products with poor bioequivalence, for which we offer an impressive proprietary portfolio of advanced delivery methods. Located in Greenville, N.C., Metrics is a proud member of Mayne Pharma. Learn more at www.metricscontractservices.com

About Mayne Pharma

Mayne Pharma is a specialty pharmaceutical company listed on the Australian Securities Exchange (ASX: MYX) focused on the application of drug delivery expertise to commercialize branded and generic pharmaceuticals, providing patients with access to better and more affordable medicines.  

Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems, and these technologies have been successfully commercialized in numerous products that have been marketed around the world. Mayne Pharma has two drug development and manufacturing facilities based in in Salisbury, Australia and Greenville, USA, with expertise in the formulation of complex oral and topical dose forms including potent compounds, modified-release products and inherently unstable compounds. For further information, visit www.maynepharma.com.  

Tom Salus, 1.252.707.6068, thomas.salus@maynepharma.com

View original content:http://www.prnewswire.com/news-releases/metrics-contract-services-adds-commercial-gerteis-roller-compaction-capabilities-300741877.html